Explain this page
Arphra AIPlain-English read on Revolution Medicines, Inc.’s valuation06-05today
AI Issuer Brief
Arphra AILoading cached brief…
Fair value
Football field →Weighted blend
—
— vs spot
Recommendation
n/a
0 of 0 methods
Method spread
0bull0bear
±5% threshold
Analyst PT consensus: $165.75 (+5.06%)
Candlestick · 1Y
Open in chart workstation →RVMD
160.06+64.74%H 166.50L 91.52MA50 122.70MA200 —Avg vol 2.3M
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.76% | +4.90% | +8.31% | +59.15% | +105.59% | +98.08% | +303.09% | +514.37% | +363.48% | +445.92% | +445.92% |
Insider · 30d
History →Bought
$0
0 txns
Sold
$0
0 txns
Net flow
+$0
Aftermarket
LiveLast trade
$158.50
Bid
$155.00
2 sh
Ask
$162.80
20 sh
Spread
$7.800
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|
Sector & industry today
LiveSectors
- Utilities+3.33%
- Financial Services+0.02%
- Industrials-0.12%
- Healthcare-0.72%
- Energy-0.94%
- Technology-0.95%
- Consumer Defensive-1.52%
- Basic Materials-1.60%
- Consumer Cyclical-1.74%
- Communication Services-1.79%
- Real Estate-2.19%
Top industries (issuer's industry highlighted)
No industry data returned.
Analyst view
Consensus target
—
No price-target data returned for this ticker.
Recent actions
0 ↑0 ↓0 hold
- No recent grade actions.
News
DB · news_items- Revolution Medicines: Strong Data, Big Market (Rating Upgrade)seekingalpha.com·Jun 13, 2026
- Can Revolution Medicines Be a Game-Changer Stock?fool.com·Jun 11, 2026
- Why Is Revolution Medicines (RVMD) Up 9.3% Since Last Earnings Report?zacks.com·Jun 05, 2026
- Revolution Medicines Is Up 97% This Year: Here Are the Bull and Bear Cases for This Soaring Biotech Stock.fool.com·Jun 05, 2026
- Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancerglobenewswire.com·May 06, 2026
- Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progressglobenewswire.com·May 06, 2026
- US FDA authorizes early access to Revolution's pancreatic cancer pillreuters.com·May 01, 2026
Recent analyst activity
DB- Jun 09, 2026PT$175.00UBS Reiterates Buy Rating on Revolution (RVMD) Following Trial Data ReleaseUBS
- Jun 09, 2026GradeBuy → BuyUBS Reiterates Buy Rating on Revolution (RVMD) Following Trial Data ReleaseUBS
- Jun 02, 2026GradeOutperform → OutperformRevolution (RVMD) PT Raised to $182 at RBC CapitalRBC Capital
- Jun 02, 2026PT$182.00Revolution (RVMD) PT Raised to $182 at RBC CapitalRBC Capital
- Jun 01, 2026PT$195.00Revolution Medicines price target raised to $195 from $169 at H.C. WainwrightH.C. Wainwright
- Jun 01, 2026GradeBuy → BuyRevolution Medicines price target raised to $195 from $169 at H.C. WainwrightH.C. Wainwright
- Jun 01, 2026GradeOutperform → OutperformWedbush reiterates Outperform on Revolution Medicines after ASCO dataWedbush
- Jun 01, 2026GradeBuy → BuyTD Cowen Reiterates Buy Rating and Top Pick on Revolution (RVMD)Cowen & Co.
- Jun 01, 2026PT$195.00Revolution Medicines price target raised to $195 from $165 at OppenheimerOppenheimer
- Jun 01, 2026GradeOutperform → OutperformRevolution Medicines price target raised to $195 from $165 at OppenheimerOppenheimer
Peers
No peer list available for RVMD.
Total assets
—
Total debt
—
Cash & equiv
—
Operating CF
—
Free cash flow
—
Buybacks
—
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
| No open-market insider activity in the recent window. | ||||
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|